Format

Send to

Choose Destination
Paediatr Respir Rev. 2013 Sep;14(3):195-8. doi: 10.1016/j.prrv.2012.11.002. Epub 2013 Mar 16.

Tolerance & resistance to β₂-agonist bronchodilators.

Author information

1
Division of Pulmonary & Sleep Medicine, Children's National Medical Center/George Washington University, Wahington DC, USA.

Abstract

For the past half-century, β₂-agonists have been the mainstay of treatment of the bronchoconstriction associated with asthma. Although their usefulness in reversing acute bronchospasm remains undiminished, there is increasing evidence that chronic use may lead to development of tolerance and thus, potentially increasing morbidity and even mortality. In addition, genetic studies have shown that certain individuals carrying specific mutations may be prone to developing resistance to β₂-agonists regardless of the duration of treatment. This article reviews the current evidence regarding the underlying mechanisms that cause or contribute to the development of the resistance, as well as the strategies for the evaluation and management of patients who are at risk for or have developed tolerance to β₂-agonists.

KEYWORDS:

Resistance; Tolerance; β(2)-agonists

PMID:
23507501
DOI:
10.1016/j.prrv.2012.11.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center